Hi George, They spent several years completing human trials &...

Hi George,

They spent several years completing human trials & capturing required clinical data for their FDA & CE submissions.
As we can all appreciate, medical devices in the biologics space require long drawn out clinical studies to confirm safety profiles, especially 3D printed no-organic material such as PCL.

Goh Khoon joined as CEO in 2016 to initiate the commercialization effort, using only seed funding they grew revenues from $200k in 2016 to just shy of a $1M in 2018 which in my opinion is impressive. Osteopore had a measly ~500k in their cash reserve before listing. The only way to scale the business was going to be through injection of more capital and thus the ASX debut. We closed 2020 with $1.5M, a clear signal that we are well truly making headwinds in market penetration.

Influencing and selling to surgeons requires significant investment in either a direct sales force or partnering with quality distributors.
This will take time, what attracts me to OSX is the 3D printing of the products significantly reduces manufacturing & labor costs.

The U.S. entry with BIOPLATE was a mess, they did not clearly inform the market (in my opinion) & then later realized their existing FDA approved Osteoplug was not suitable for the U.S. market. As far as I understand it, a new FDA submission is now required. I hope Carl provides a clearer update about this in the coming quarterly.

I am optimistic about the ANZ sales efforts through LMT surgical, a very well known distributor here in Australia.
Likewise, the new product developments mentioned in their recent quarterly show a good pipeline of expanding our addressable market.



Also highlighting out our 2nd generation product pipeline, yet to hear more but will certainly be an interesting catalyst.




I am confident revenue will continue to grow and new products joining the portfolio will compound that growth.
$50M market cap is too cheap, the pump from the IPO is well truly over.

Once this gets in the front of investors & traders again, it will run.